Pfizer Australia, BioNTech SE and Novavax are ready to roll out vaccines against coronavirus in Australia and further afield.
Pfizer Australia and BioNTech SE have an agreement with Australia to supply 10 million doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2 in 2021.
Financial details of the Pfizer Australia and BioNTech SE agreement have not been disclosed, but the terms are based on the timing of delivery and the volume of doses.
Deliveries are planned in 2021 subject to clinical success and local regulatory approval.
In addition to engagements with governments, Pfizer and BioNTech have provided an expression of interest for possible supply to the COVAX Facility, a mechanism established by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organisation (WHO).
The objective is to provide governments, including those in the emerging markets, with early access to a large portfolio of Covid-19 candidate vaccines using a range of technology platforms, produced by multiple manufacturers across the world.
In addition, Novavax, a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, has announced the signing of a non-binding Heads of Terms document with the Australian Government to supply 40 million doses of the company’s Covid-19 vaccine candidate, NVX-CoV2373, for the Australian community.
